Compare UAMY & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAMY | PACB |
|---|---|---|
| Founded | 1968 | 2000 |
| Country | United States | United States |
| Employees | N/A | 575 |
| Industry | Metal Fabrications | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 829.0M | 715.5M |
| IPO Year | N/A | 2010 |
| Metric | UAMY | PACB |
|---|---|---|
| Price | $6.00 | $2.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $5.69 | $2.00 |
| AVG Volume (30 Days) | 8.5M | ★ 8.6M |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $31,857,819.00 | ★ $154,584,000.00 |
| Revenue This Year | $159.13 | $4.41 |
| Revenue Next Year | $228.42 | $11.76 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 177.97 | N/A |
| 52 Week Low | $1.21 | $0.85 |
| 52 Week High | $19.71 | $2.73 |
| Indicator | UAMY | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 50.39 |
| Support Level | $5.16 | $2.30 |
| Resistance Level | $6.95 | $2.47 |
| Average True Range (ATR) | 0.49 | 0.23 |
| MACD | 0.13 | -0.01 |
| Stochastic Oscillator | 46.37 | 36.75 |
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.